BENEFITS OF
NINLARO® (IXAZOMIB)

Man and woman looking at a tablet together.

Overview of the NINLARO study*

The treatment combination of NINLARO+lenalidomide+dexamethasone was tested in a clinical study compared to placebo+lenalidomide+dexamethasone in people whose multiple myeloma had returned. This study evaluated the efficacy and safety profile of NINLARO in combination with lenalidomide+dexamethasone.

The study compared a three medication vs a two medication combination

The NINLARO® (ixazomib) combination consisting of NINLARO, lenalidomide, and dexamethasone vs a placebo, lenalidomide, and dexamethasone combination

*The US Food and Drug Administration (FDA) approved NINLARO based on the results of this clinical study. This study tested the NINLARO treatment combination (NINLARO+lenalidomide+dexamethasone) compared with placebo+lenalidomide+dexamethasone in 722 people whose multiple myeloma had come back or stopped responding to prior therapy. It measured the length of time a patient lived without their disease getting worse.
Placebo pills are not active.

When multiple myeloma returns, taking the NINLARO treatment combination may help you live longer without your multiple myeloma getting worse

The NINLARO treatment combination (NINLARO+lenalidomide+dexamethasone) was proven to be an effective treatment for people whose multiple myeloma had come back or stopped responding to prior therapy.

Progression-free survival (PFS)

In the clinical study, people taking the NINLARO treatment combination went more than a year and a half (20.6 months) without their multiple myeloma getting worse compared to 14.7 months for people who took the lenalidomide+dexamethasone combination alone.

The NINLARO treatment combination improved the
time people lived without their disease getting worse

The NINLARO® (ixazomib) combination had a 6-month improvement in PFS in comparison to the lenalidomide+dexamethasone combination.

NINLARO combination=NINLARO+lenalidomide+dexamethasone; lenalidomide+dexamethasone combination=placebo+lenalidomide+dexamethasone.

Overall survival

In this study, people taking the NINLARO treatment combination lived a similar overall length of time after diagnosis as people who received the lenalidomide+dexamethasone combination alone.

The NINLARO treatment combination was proven to work quickly and effectively

Ten people icons with 8 out of the 10 filled in.
Most people had a response.

78% of people responded to the NINLARO treatment combination (vs 72% with the lenalidomide+dexamethasone combination). Of those people, 48% had a very good partial response (VGPR)§ or a complete response (CR)‖‖

 

1.1 months.
Fast responses.

The NINLARO treatment combination was proven to work fast. Of the people who responded to it, half of them saw their first response in less than 1.1 months (the other half taking the NINLARO treatment combination took longer to see a response) compared with about 2 months for the lenalidomide+dexamethasone combination.
 

Down arrow icon above M protein.
Deepened responses over time.

Response to the NINLARO treatment combination deepened with more time on treatment. For example, twice as many people saw a complete response|| to treatment (disappearance of the M protein) after 12 months compared to after 6 months. Responses improved over time for both treatment combinations in the study.


§A 90% or greater decrease in M protein (an abnormal myeloma protein produced by myeloma cells). Also called very good partial remission.
‖‖Complete response is when there are less than 5% plasma cells in the bone marrow and blood and urine lab tests show no M protein.

Terms and Conditions apply

By enrolling in the Takeda Oncology Co-Pay Assistance Program (the “Program”), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:

You must be at least 18 years old, a resident of the United States or a US Territory, and have commercial (private) prescription insurance that does not cover the entire cost of the medication. The Program is not valid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicare, Medicare Advantage, Medigap, Medicaid, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who become eligible for or start using government insurance will no longer be eligible for the Program. The Program is not valid if the entire cost of your prescription is reimbursable by a private insurance plan or other private health or pharmacy benefit programs. You are responsible for reporting receipt of Program assistance to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost, as may be required.

You agree that you will not submit the cost of any portion of the product dispensed pursuant to this Program to a federal or state healthcare program (including, but not limited to, Medicare, Medicare Advantage, Medicaid, TRICARE, VA, DOD, etc.), for purposes of counting it toward your out-of-pocket expenses, and to notify Takeda Oncology Here2Assist® if you become eligible for a federal or state healthcare program. This Program is not conditioned on any past, present or future purchase of any Takeda product, including refills. This Program is valid for 12 months, and your co-pay card may be renewed every 12 months, subject to continued eligibility. This offer is not valid with any other program, discount, or offer involving your prescribed Takeda Oncology medication. This offer may be rescinded, revoked, or amended without notice. No reproductions. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. No income requirements or membership fees. This Program is not health insurance. Cash value of 1/100 of 1¢. For questions about this offer, please contact the Takeda Oncology Co-Pay Assistance Program, a patient support service of Takeda Oncology Here2Assist, at 1-844-817-6468, Option 2, Monday-Friday, 8AM-8PM ET.

Side effects
with NINLARO

Get details about potential side effects for
the NINLARO treatment combination.

Takeda Oncology
Here2Assist® patient support

Learn how we can help with coverage, financial,
and educational resource needs.